Bryan Clemons

1.2k total citations · 1 hit paper
13 papers, 999 citations indexed

About

Bryan Clemons is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Bryan Clemons has authored 13 papers receiving a total of 999 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Rheumatology. Recurrent topics in Bryan Clemons's work include Sphingolipid Metabolism and Signaling (6 papers), Pulmonary Hypertension Research and Treatments (3 papers) and Receptor Mechanisms and Signaling (2 papers). Bryan Clemons is often cited by papers focused on Sphingolipid Metabolism and Signaling (6 papers), Pulmonary Hypertension Research and Treatments (3 papers) and Receptor Mechanisms and Signaling (2 papers). Bryan Clemons collaborates with scholars based in United States, Sweden and Norway. Bryan Clemons's co-authors include Fiona L. Scott, Hugh Rosen, Stuart M. Cahalan, Gye Won Han, C. Roth, Stephan C. Schuerer, Raymond C. Stevens, Marta Sanna, Mark T. Griffith and Euijung Jo and has published in prestigious journals such as Science, Circulation and Gastroenterology.

In The Last Decade

Bryan Clemons

12 papers receiving 966 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Crystal Structure of a Lipid G Protein–Coupled Receptor

2012 544 citations Michael A. Hanson, C. Roth et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bryan Clemons United States	7	751	233	107	104	75	13	999
Moulay Driss Rochdi Canada	14	552 0.7×	195 0.8×	132 1.2×	70 0.7×	68 0.9×	15	817
Roland Neuhaus Germany	16	732 1.0×	193 0.8×	83 0.8×	76 0.7×	32 0.4×	35	1.1k
Chie Sakanaka Japan	20	1.3k 1.7×	247 1.1×	133 1.2×	191 1.8×	38 0.5×	26	1.7k
Patrick Kaminker United States	17	1.0k 1.4×	139 0.6×	60 0.6×	116 1.1×	43 0.6×	24	1.6k
Rulin Zhang China	13	570 0.8×	235 1.0×	113 1.1×	112 1.1×	23 0.3×	27	1.2k
Yuh‐Jin Liang Taiwan	24	877 1.2×	126 0.5×	113 1.1×	120 1.2×	28 0.4×	40	1.5k
Hye Shin Lee South Korea	19	820 1.1×	154 0.7×	171 1.6×	167 1.6×	27 0.4×	28	1.2k
Norikazu Mizuno Japan	16	763 1.0×	264 1.1×	141 1.3×	77 0.7×	64 0.9×	20	1.0k
Susan Giblett United Kingdom	17	695 0.9×	130 0.6×	202 1.9×	166 1.6×	23 0.3×	25	1.3k
Edith López Mexico	17	426 0.6×	159 0.7×	135 1.3×	68 0.7×	88 1.2×	34	797

Countries citing papers authored by Bryan Clemons

Since Specialization

Citations

This map shows the geographic impact of Bryan Clemons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Clemons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Clemons more than expected).

Fields of papers citing papers by Bryan Clemons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan Clemons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Clemons. The network helps show where Bryan Clemons may publish in the future.

Co-authorship network of co-authors of Bryan Clemons

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan Clemons. A scholar is included among the top collaborators of Bryan Clemons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan Clemons. Bryan Clemons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Galkin, Anna, Ravikumar Sitapara, Bryan Clemons, et al.. (2022). Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. European Respiratory Journal. 60(6). 2102356–2102356. 49 indexed citations

Galkin, Anna, et al.. (2020). Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH). 3550–3550. 1 indexed citations

Galkin, Anna, et al.. (2019). Abstract 11102: Gb002, A Novel Inhaled Pdgfr Kinase Inhibitor, Demonstrates Efficacy in the Su5416 Hypoxia Rat Model of Pulmonary Arterial Hypertension (pah). Circulation. 4 indexed citations

Steinberg, Marcos W., et al.. (2018). Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. PLoS ONE. 13(4). e0193236–e0193236. 40 indexed citations

Akhtar, Mohd Waseem, Christiane Villescaz, Bryan Clemons, et al.. (2018). Ozanimod (RPC1063) Preserves Central Nervous System (CNS) Tissue in Rodents by Reducing Neuronal Breaks in Vivo and Modulating Astrocyte Activity in Vitro (P5.027). Neurology. 90(15_supplement). 1 indexed citations

Scott, Fiona L., Bryan Clemons, Jennifer L. Brooks, et al.. (2016). Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P ₁ ) and receptor‐5 (S1P ₅ ) agonist with autoimmune disease‐modifying activity. British Journal of Pharmacology. 173(11). 1778–1792. 239 indexed citations

Scott, Fiona L., Gregg Timony, Jennifer L. Brooks, et al.. (2013). Metabolites of RPC1063 Contribute to In Vivo Efficacy (P05.157). Neurology. 80(7_supplement). 4 indexed citations

Brooks, Jennifer L., Robert Peach, Marcus F. Boehm, et al.. (2013). Sa1221 Rpc1063, a Potent, Selective S1P1 Receptor Modulator, Is Active in a Therapeutic IBD Model and Exhibits Favorable PK/PD Properties in Healthy Volunteers. Gastroenterology. 144(5). S–234. 3 indexed citations

Hanson, Michael A., C. Roth, Euijung Jo, et al.. (2012). Crystal Structure of a Lipid G Protein–Coupled Receptor. Science. 335(6070). 851–855. 544 indexed citations breakdown →

10.

Clemons, Bryan, Harry Dedman, Rachel Powell, et al.. (2012). 358 A Small Molecule S1P1 Receptor Agonist With Significant Efficacy in Animal Models of Inflammatory Bowel Disease (IBD). Gastroenterology. 142(5). S–84. 1 indexed citations

11.

Cahalan, Stuart M., Pedro J. Gonzalez‐Cabrera, Gor Sarkisyan, et al.. (2011). Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice. Nature Chemical Biology. 7(5). 254–256. 65 indexed citations

12.

Lehmann, Fredrik, Erika A. Currier, Bryan Clemons, et al.. (2009). Novel and potent small-molecule urotensin II receptor agonists. Bioorganic & Medicinal Chemistry. 17(13). 4657–4665. 6 indexed citations

13.

Gardell, Luis R., Hans H. Schiffer, Ali Tabatabaei, et al.. (2008). Identification and Characterization of Novel Small-Molecule Protease-Activated Receptor 2 Agonists. Journal of Pharmacology and Experimental Therapeutics. 327(3). 799–808. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact